Navigation Links
Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
Date:6/16/2009

healthy tissue. In a previous clinical study, a subset of patients with recurrent glioblastoma treated with Cotara achieved a median survival of 38 weeks, a 58% increase over the historical median survival time of 24 weeks for patients treated with standard of care therapy. In this study, 25% of 28 recurrent patients survived for more than a year post-treatment and 10% of patients survived for more than three years. These data are considered a promising development in this deadly disease. Cotara has been granted orphan drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration. A Phase I dosimetry trial in GBM patients in the U.S. is in the final stages of patient enrollment and a Phase II safety and efficacy trial in GBM patients in India is ongoing. For more information on the trials, visit www.clinicaltrials.gov.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals'
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
5. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
6. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
7. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
8. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
9. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
10. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
11. Promising Data ATIR Studies Presented by NIH Investigators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 2008,November 4th through 9th,in Philadelphia, Pennsylvania, MISGAV, ... is pleased to announce encouraging preliminary data for ... I/II clinical trial of Medgenics, EPODURE Biopump,for providing ... kidney,disease, is underway. The current trial is designed ...
... Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biopharmaceutical company ... for,the treatment of solid and hematologic cancers, today announced ... conferences:, Rodman & Renshaw 10th Annual Healthcare Conference, ... Wednesday, November 12, 2008, 2:00 p.m. EST, ...
... JERSEY CITY, New Jersey, November 3, Rosetta Genomics ... development of microRNA-based diagnostics, announced today it will,present ... the Lab and Clinic in Cancer Medicine" Molecular ... take place,between November 3-6, at the ICC Jerusalem ...
Cached Biology Technology:Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia 2Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia 3Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia 4Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia 5Sunesis to Present at Upcoming Conferences 2Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference 2Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference 3
(Date:4/15/2014)... study the deadliest infectious diseases recognized the contributions of ... the University of Texas Medical Branch, with a Lifetime ... Filoviruses. The filoviruses include Ebola and Marburg viruses that ... infected. The current outbreak of Ebola virus raging in ... far. , "This award represents the culmination of ...
(Date:4/15/2014)... University dental researchers have found a less invasive ... the mouth to study how the mouth,s natural ... isolating some specialized immune cells (white blood cells ... diseases in the mouthor reject foreign tissues, such ... more about treating and preventing such health issues ...
(Date:4/15/2014)... 2014) The American Association of Anatomists (AAA) is ... awards will be presented during the Closing Awards Ceremony ... Tuesday, April 29th at 7:30 p.m. during AAA,s 2014 ... The 2014 award winners are: , Henry ... the Icahn School of Medicine at Mount Sinai, Past-President ...
Breaking Biology News(10 mins):International research group recognizes UTMB experts 2International research group recognizes UTMB experts 3New method isolates immune cells for researchers to study how they ward off oral diseases 2American Association of Anatomists 2014 award winners 2
... the meaning of a rare mineral that can be used to ... and others better understand what we,re probably in for over the ... the heat and, ultimately, to change life as we know ... place in the next hundred years or so, and that many ...
... colloquium to examine what lies ahead in evolutionary studies ... and students will discuss new tools to predict future ... of ecology, paleontology, phylogenetics, and biodiversity informatics dealing with ... series, the event will take place at the Arnold ...
... (ST. LOUIS): The Missouri Botanical Garden Press (MBG ... species of vascular plants for the Southern Cone region, ... Plantas Vasculares del Cono Sur (Catalogue of the Plants ... the plants of Argentina, southern Brazil, Chile, Paraguay and ...
Cached Biology News:Foretelling a major meltdown 2Foretelling a major meltdown 3Missouri Botanical Garden publishes first catalogue of plants of the Southern Cone 2
hnRNP U (H-94)...
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
... GELase™ Agarose Gel-Digesting Preparation contains a ... for simple, quantitative recovery of intact DNA ... agarose gels following electrophoresis in TAE, TBE, ... be digested directly in the TAE, TBE, ...
... in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and ... royalties for your hard work and endeavour! ... build it up,and market it internationally. We ...
Biology Products: